Article

Novel compound shows promise for dry eye in proof-of-concept study

Topical drug for the treatment of dry eye disease sees potential 

Eric D. Donnenfeld, MD, FAAO, shares results from an ex-U.S. proof-of-concept study investigating a novel, small peptide anti-integrin topical therapy (ALG-1007, Allegro Ophthalmics) for the treatment of dry eye disease. He presented his research at the 2019 annual ASCRS meeting in San Diego.

RELATED: Sustained-release implant promising for long-term IOP reduction

Related Videos
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
© 2024 MJH Life Sciences

All rights reserved.